Migraine remains one of the most disabling disorders worldwide. The high 
prevalence in the general population and the often-delicate treatment of 
patients account for that. Therapeutic management of migraine relies mainly on 
non-specific medical treatment and is affected by low patient adherence to the 
treatment regimens applied. The introduction of specific anti-migraine treatment 
occurred over 20 years ago when the first triptan was approved by regulatory 
authorities (sumatriptan, 28 December 1992). Triptan use is limited by side 
effects, time- and frequency-restricted application, and the risk of developing 
medication overuse headache. Within the past few years, new and promising drugs 
such as more specific 5-HT 1F receptor agonists (that is, lasmiditan) and 
monoclonal calcitonin gene-related peptide (CGRP) receptor antibodies entered 
advanced development phases while non-invasive neuromodulatory approaches were 
suggested to be potentially effective as non-pharmaceutical interventions for 
migraine.